Trial · NCT03583372
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any TEAE | 171 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any TEAE | 126 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any study drug-related TEAE | 59 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any study drug-related TEAE | 46 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any Grade ≥ 3 TEAE | 10 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any Grade ≥ 3 TEAE | 8 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any Grade ≥ 3 study drug-related TEAE | 1 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any Grade ≥ 3 study drug-related TEAE | 1 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any treatment-emergent (TE) SAE | 9 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any treatment-emergent (TE) SAE | 10 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any study drug-related TE SAE | 1 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any study drug-related TE SAE | 2 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any TEAE leading to discontinuation of study drug | 4 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any TEAE leading to discontinuation of study drug | 8 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any TEAE of clinical interest | 41 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any TEAE of clinical interest | 32 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Vibegron 75 mg | Any study drug-related TEAE of clinical interest | 14 | participants | |
| Number of Participants With the Indicated Type of Treatment-emergent Adverse Event | Overall Tolterodine ER 4 mg | Any study drug-related TEAE of clinical interest | 10 | participants | |
| Change From Baseline (CFB) at Week 52 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants | 52 Weeks Vibegron 75 mg | -2.4 | Standard Error 0.24 | micturitions per 24 hours | |
| Change From Baseline (CFB) at Week 52 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants | 52 Weeks Tolterodine ER 4 mg | -2.0 | Standard Error 0.26 | micturitions per 24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03583372/results